Investment Thesis
FONAR displays a fortress balance sheet with zero meaningful debt and exceptional liquidity, but is fundamentally a stagnant business with flat net income growth (0% YoY) and anemic free cash flow conversion (1.3% margin). Weak capital returns (ROE 3.3%, ROA 2.7%) and absence of insider buying signal limited growth prospects and inefficient capital deployment.
Strengths
- Zero long-term debt with $53.6M cash position provides financial stability
- Exceptional liquidity (9.18x current ratio) reduces bankruptcy risk
- Solid operating profitability (12.7% operating margin) in medical device sector
Risks
- Stagnant growth: 1.4% revenue and 0% net income growth indicates mature/declining business
- Poor capital efficiency: ROE 3.3% and ROA 2.7% suggest excess cash sitting idle without productive deployment
- Weak cash generation: $1.0M free cash flow on $6.0M net income indicates working capital issues or capital intensity mismatch
Key Metrics to Watch
- Revenue growth trajectory (need reversal from 1.4% stagnation)
- Free cash flow margin expansion (currently only 1.3%, well below net margin of 7.6%)
- Return on equity improvement (3.3% is well below cost of capital for equity holders)
Financial Metrics
Revenue
78.1M
Net Income
6.0M
EPS (Diluted)
$1.16
Free Cash Flow
1.0M
Total Assets
219.2M
Cash
53.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
12.7%
Net Margin
7.6%
ROE
3.3%
ROA
2.7%
FCF Margin
1.3%
Balance Sheet & Liquidity
Current Ratio
9.18x
Quick Ratio
9.00x
Debt/Equity
0.00x
Debt/Assets
25.0%
Interest Coverage
148.42x
Long-term Debt
7.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:16:57.704138 |
Data as of: 2026-03-31 |
Powered by Claude AI